BLUECORE's PICORE MAX Receives U.S. FDA 510(k) Clearance

BLUECORE COMPANY is pleased to announce that PICORE MAX, its advanced picosecond laser platform featuring proprietary Diffractive Microlens Array (DLA) technology, has received U.S. FDA 510(k) clearance, marking a significant milestone in the company's global expansion.
The achievement was recently featured in SegyeBiz, highlighting PICORE MAX's proprietary DLA technology and its significance in advancing picosecond laser technology.
PICORE MAX has received FDA 510(k) clearance for specific applications, including tattoo removal and the treatment of certain benign pigmented lesions, wrinkles, and acne scars, with cleared indications varying by wavelength, handpiece, and skin type.
The article also explores the potential of picosecond laser-based facial contouring, reflecting ongoing research into broader applications of laser technology in medical aesthetics.
Building on this regulatory milestone, BLUECORE aims to strengthen its presence in the U.S. market and continue expanding its global reach through advanced laser technologies.
Read the full article:
Source: SegyeBiz | November 4, 2026




